Volume 8, Number 8—August 2002
DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice
|Immunization||No. mice||Lung titer +/- SE|
|A/NP+A/M DNA||6||5.7 ± 0.33|
|B/NP + blank DNA||6||6.9 ± 0.18b|
|None||6||6.9 ± 0.22c|
|Live X-31 virus||4||3.6 ± 0.36d|
|None||4||7.1 ± 0.1|
aMice were immunized intramuscularly with 100 μg each of influenza A nucleoprotein and matrix DNA (A/NP+A/M DNA) or controls with 100 μg each of influenza B nucleoprotein DNA (B/NP)+blank DNA (total dose 200 μg/mouse on each occasion), three times at 2-week intervals. Two weeks after the last dose of DNA, mice were challenged with 100 mouse infectious dose (MID)50 of HK/486 intranasally. X31 virus-primed mice and their controls were challenged along with DNA-vaccinated mice. On day 6 after challenge, mice were sacrificed and lungs collected for titration of virus infectivity.
bDiffers significantly from A/NP+A/M group by analysis of variation (ANOVA), p=0.0082.
cDiffers significantly from A/NP+A/M group by ANOVA, p=0.011.
dDiffers significantly from unimmunized group by ANOVA, p<0.001.
- Page created: July 16, 2010
- Page last updated: July 16, 2010
- Page last reviewed: July 16, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)